Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
17.29
-0.99 (-5.42%)
May 15, 2026, 4:00 PM EDT - Market closed
Dyne Therapeutics Employees
Dyne Therapeutics had 263 employees as of March 31, 2026. The number of employees increased by 71 or 36.98% compared to the same quarter last year.
Employees
263
Change
71
Growth
36.98%
Revenue / Employee
n/a
Profits / Employee
-$1,717,517
Market Cap
2.86B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 263 | 71 | 36.98% |
| Dec 31, 2025 | 258 | 67 | 35.08% |
| Sep 30, 2025 | 240 | 67 | 38.73% |
| Jun 30, 2025 | 206 | 54 | 35.53% |
| Mar 31, 2025 | 192 | 49 | 34.27% |
| Dec 31, 2024 | 191 | 50 | 35.46% |
| Sep 30, 2024 | 173 | 37 | 27.21% |
| Jun 30, 2024 | 152 | 18 | 13.43% |
| Mar 31, 2024 | 143 | 21 | 17.21% |
| Dec 31, 2023 | 141 | 22 | 18.49% |
| Sep 30, 2023 | 136 | 21 | 18.26% |
| Jun 30, 2023 | 134 | 26 | 24.07% |
| Mar 31, 2023 | 122 | 26 | 27.08% |
| Dec 31, 2022 | 119 | 26 | 27.96% |
| Sep 30, 2022 | 115 | 27 | 30.68% |
| Jun 30, 2022 | 108 | 37 | 52.11% |
| Mar 31, 2022 | 96 | 40 | 71.43% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcus Biosciences | 601 |
| Beam Therapeutics | 522 |
| Denali Therapeutics | 507 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Vera Therapeutics | 249 |
| Alumis | 224 |
| Structure Therapeutics | 220 |
DYN News
- 1 day ago - Dyne Therapeutics price target lowered to $33 from $34 at Evercore ISI - TheFly
- 3 days ago - Dyne Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 days ago - Dyne Therapeutics price target raised to $24 from $23 at Bernstein - TheFly
- 4 days ago - Dyne Therapeutics reports Q1 EPS (73c), consensus (78c) - TheFly
- 5 days ago - Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 18 days ago - Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting - GlobeNewsWire
- 22 days ago - Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines - GlobeNewsWire